ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.187
AS - Asia 17.083
EU - Europa 9.265
SA - Sud America 2.419
AF - Africa 412
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 17
Totale 59.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.564
SG - Singapore 5.056
CN - Cina 3.372
HK - Hong Kong 3.006
VN - Vietnam 2.022
BR - Brasile 1.827
GB - Regno Unito 1.827
IT - Italia 1.741
FI - Finlandia 1.136
BD - Bangladesh 1.076
SE - Svezia 1.060
KR - Corea 713
RU - Federazione Russa 707
DE - Germania 626
FR - Francia 377
BG - Bulgaria 372
IN - India 357
PL - Polonia 356
CA - Canada 318
AR - Argentina 237
TR - Turchia 235
ID - Indonesia 226
NL - Olanda 174
UA - Ucraina 173
JP - Giappone 161
MX - Messico 155
ZA - Sudafrica 149
IQ - Iraq 144
AE - Emirati Arabi Uniti 124
ES - Italia 120
AT - Austria 106
CO - Colombia 80
LT - Lituania 76
PK - Pakistan 75
EC - Ecuador 74
IE - Irlanda 74
EG - Egitto 59
CL - Cile 55
SA - Arabia Saudita 54
MA - Marocco 53
CZ - Repubblica Ceca 51
UZ - Uzbekistan 51
PH - Filippine 46
VE - Venezuela 45
MY - Malesia 43
BE - Belgio 40
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 36
RO - Romania 36
AU - Australia 33
TN - Tunisia 31
CR - Costa Rica 30
KZ - Kazakistan 28
IL - Israele 26
NP - Nepal 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
TH - Thailandia 22
CH - Svizzera 21
AL - Albania 20
ET - Etiopia 20
UY - Uruguay 20
IR - Iran 19
GR - Grecia 18
HN - Honduras 18
BO - Bolivia 17
NO - Norvegia 17
DO - Repubblica Dominicana 16
JM - Giamaica 15
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
BH - Bahrain 14
PT - Portogallo 14
TW - Taiwan 14
DK - Danimarca 13
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
LB - Libano 12
MK - Macedonia 12
GE - Georgia 11
MD - Moldavia 11
PR - Porto Rico 11
HU - Ungheria 10
LV - Lettonia 10
QA - Qatar 10
EE - Estonia 9
GT - Guatemala 9
BY - Bielorussia 8
KH - Cambogia 8
CY - Cipro 7
HR - Croazia 7
NI - Nicaragua 7
SK - Slovacchia (Repubblica Slovacca) 7
TT - Trinidad e Tobago 7
BA - Bosnia-Erzegovina 6
LA - Repubblica Popolare Democratica del Laos 6
PA - Panama 6
Totale 59.305
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.620
Ashburn 3.470
Singapore 3.254
Hong Kong 2.964
Fairfield 2.373
Chandler 2.080
Helsinki 1.087
New York 1.005
London 989
San Jose 924
Nyköping 857
Woodbridge 848
Houston 804
Wilmington 755
Seattle 702
Hefei 701
Los Angeles 670
Ho Chi Minh City 640
Cambridge 626
Beijing 601
Seoul 588
The Dalles 565
Hanoi 503
Chicago 496
Council Bluffs 495
Ann Arbor 475
San Diego 470
Princeton 372
Sofia 359
Southend 344
Warsaw 335
Milan 271
Buffalo 250
Moscow 221
Orem 212
Shanghai 195
Salt Lake City 190
Modena 184
Jersey City 180
São Paulo 172
Piscataway 162
Dallas 155
Jakarta 154
Jacksonville 153
Dearborn 152
Secaucus 123
Tokyo 118
Redondo Beach 115
Da Nang 110
Istanbul 105
Phoenix 101
Porto Alegre 97
Rome 95
Frankfurt am Main 93
North Bergen 91
Lauterbourg 89
Haiphong 87
Johannesburg 87
Bremen 86
Chennai 86
Bupyeong-gu 84
Atlanta 80
Denver 78
Toronto 78
Newark 77
Tampa 75
Brooklyn 73
Bologna 68
Dublin 68
Elk Grove Village 66
Munich 66
San Francisco 66
Vienna 66
Montreal 61
Amsterdam 59
Norwalk 57
Mexico City 56
Clifton 54
Rio de Janeiro 54
Miano 52
Nuremberg 52
Stockholm 51
Viroflay 51
Manchester 49
Paris 49
Guangzhou 48
Izmir 48
Augusta 47
Charlotte 47
Baghdad 45
Des Moines 44
Kent 44
Kilburn 44
Tashkent 44
Biên Hòa 43
Boardman 43
Dhaka 43
Mumbai 43
Naples 43
Boston 41
Totale 40.363
Salva come PNG Salva come JPEG
Nome #
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 840
Non-alcoholic steatohepatitis and liver transplantation 524
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis 388
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 386
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 384
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 361
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 349
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 338
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 335
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 322
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 322
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 316
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 315
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 307
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 305
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 295
From current status to optimization of HCV treatment: Recommendations from an expert panel 295
Missed treatment in an Italian HBV infected patients cohort: HBV RER 294
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 286
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 280
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 276
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 270
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 266
Global multi-stakeholder endorsement of the MAFLD definition 265
Treatment of nonalcoholic steatohepatitis in adults: present and future 259
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 258
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 256
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 254
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 249
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 248
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 247
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 246
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 241
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 239
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 239
Adaptive response in Hepatitis B virus infection 239
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 238
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 236
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 235
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 235
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 234
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 227
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 225
Characteristics of hepatocellular carcinoma in Italy 225
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 225
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 224
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 222
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 222
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 219
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 219
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 218
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 214
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 214
Alcohol and viral hepatitis: a mini-review 214
Update on Alcohol and Viral Hepatitis 212
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 210
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 209
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 208
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 208
CD 133+ stem cells for the treatment of end stage liver disease 204
Gross pathologic types of hepatocellular carcinoma in Italy. 203
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 203
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 202
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 202
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 202
Clinical and serological profile of primary biliary cirrhosis in men 201
Detection of HCV antigens in liver graft: Relevance to the management of recurrent post-liver transplant hepatitis C 201
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 201
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 200
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 200
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 199
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 199
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 198
Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods 198
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 197
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 196
COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs 196
Chronic hepatitis B: Are we close to a cure? 195
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 194
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 194
Familial intrahepatic cholestasis: New and wide perspectives 189
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 189
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 188
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 187
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 187
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 187
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 186
Virological Treatment Monitoring for Chronic Hepatitis B 184
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 183
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 183
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 182
Characterization of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver 182
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 182
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 181
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 181
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 180
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 179
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 179
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 179
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 178
Totale 24.238
Salva come PNG Salva come JPEG
Categoria #
all - tutte 303.227
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 303.227
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021136 0 0 0 0 0 0 0 0 0 0 0 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202627.347 1.254 771 1.909 2.610 3.282 2.815 3.028 1.652 2.575 2.524 2.528 2.399
Totale 59.953